CUSIP: 29428P107
Q1 2015 13F Holders as of 31 Mar 2015
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
13,448,067
-
Share change
-
+10,412,851
-
Total reported value
-
$120,415,000
-
Price per share
-
$8.95
-
Number of holders
-
41
-
Value change
-
+$93,386,700
-
Number of buys
-
38
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 29428P107?
CUSIP 29428P107 identifies EPRSQ - EPIRUS BIOPHARMACEUTICALS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2015
-
Previous quarter:
Q4 2014
Recent filing periods for CUSIP 29428P107:
Institutional Holders of EPIRUS BIOPHARMACEUTICALS IN - COM (EPRSQ) as of Q1 2015
As of 31 Mar 2015,
EPIRUS BIOPHARMACEUTICALS IN - COM (EPRSQ) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,448,067 shares.
The largest 10 holders included
JENNISON ASSOCIATES LLC, TPG Group Holdings (SBS) Advisors, Inc., Camber Capital Management LLC, Consonance Capital Management LP, FMR LLC, Cormorant Asset Management, LLC, Broadfin Capital, LLC, ADAGE CAPITAL PARTNERS GP LLC, VANGUARD GROUP INC, and Lombard Odier Asset Management (USA) Corp.
This page lists
41
institutional shareholders reporting positions in this security
for the Q1 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.